The global urinary tract infection testing market was valued at US$ 563.0 Million in 2022 and is expected to reach US$ 1.1 Billion by 2033. The urinalysis test with around 48.5% in terms of value share, has topped the global market within the testing category in 2022 and is expected to grow at a CAGR of close to 6.0% over the forecast period (2023 to 2033)
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2022 | US$ 563.0 Million |
Market Value 2023 | US$ 593.7 Million |
Market Value 2033 | US$ 1.1 Billion |
CAGR 2023 to 2033 | 6.0% |
Market Share of Top 5 Countries | 53.5% |
Key Market Players | ACON Laboratories Inc.; Cardinal Health Inc.; Danaher Corporation; SYSMEX CORPORATION; Abbott Laboratories; Bio-Rad Laboratories; Roche AG; LabCorp(Laboratory Corporation of America Holdings).; Stryker Corporation; Thermo Fisher Scientific, Inc. |
Globally, the number of people suffering from urinary tract infections has increased. Urinary tract infection adds to the world's second-largest patient pool. The market is expected to rise because of rising UTI prevalence and desire for better treatment options. The introduction of innovative testing kits and equipment is likely to propel the urine infection testing industry forward.
With the introduction of new technologies and an increase in the number of urinary tract infection testing kits and device players, the urinary tract infection testing market is likely to expand over the upcoming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for urinary tract infection testing was around 1.6% of the US$ 35.0 Billion of the global infectious disease diagnostics market in 2022.
One of the most prevalent bacterial infections, impacting almost 150 million individuals worldwide, is urinary tract infection. Urinary tract infection is most commonly caused by bacteria, viruses, and fungus in the urinary tract. Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Proteus species, and Enterococcus species are few bacteria that cause urinary tract infections.
There is a growing interest in developing creative and effective technology that can quickly and reliably identify UTIs and select the optimum antibiotic to use for a specific patient. This, along with the other factors mentioned, are projected to drive the market in the coming year.
Owed to the above factors, the global market is projected to grow at CAGR of 6.0% in forecasted period.
Recurrence of urinary tract infections is very common, even in uncomplicated cases.
Bacterial persistence occurs when treatment is hampered by the buildup of germs in an area that antibiotics cannot reach, such as infected stones, urethral diverticula, and infected paraurethral glands.
Urinary tract infections are also rather common in males. Prostatitis, pyelonephritis, urethritis, cystitis, epididymitis, orchitis, and infected urinary catheters are all included in the group of adult male UTIs. Due to the numerous defenses the male urinary system has, any such infections are typically linked to anatomical anomalies that frequently call for surgical repair.
The increasing incidence of chronic kidney disease, such as renal failure and bladder cancer, is driving the use of catheters and other drainage devices in patients. Patients with urinary catheters are more likely to contract a complicated UTI. This is expected to boost growth in the UTI testing market over the forecast period.
Bacteria enter the urinary system through improper catheter insertion technique or inadequate cleanliness, resulting in infection. Poor hygiene habits, such as neglecting to clean the catheter or drainage bag, might encourage bacterial development and raise the possibility of UTIs. Sometimes, catheters can cause urine to build up or stagnate in the bladder, which can foster the growth of germs. Additionally, blockages in the catheter can prevent urine from flowing normally, causing urinary stasis and a higher risk of infection. All of these factors result in a high demand for testing for UTI.
The accuracy of UTI diagnostic tests varies, which might result in false-positive or false-negative results. This can lead to incorrect diagnosis and treatment recommendations. The limitations of existing diagnostic tests may impede their acceptance and limit the growth of the UTI testing market. The inappropriate and overuse of antibiotics in UTI care can have an impact on the need for UTI testing. Overuse of empirical antibiotic treatment without sufficient diagnostic confirmation can lessen the perceived necessity for diagnostic testing, resulting in UTI test underutilization. Efforts to promote ethical antibiotic usage and evidence-based diagnosis may influence UTI testing demand.
Urine samples are frequently required for UTI diagnostic tests. Obtaining clean-catch urine samples can be difficult, particularly in specific patient populations such as children, the elderly, or those with mobility challenges. Difficulties in collecting samples may have an impact on the accuracy and reliability of UTI tests, limiting their usage.
The USA occupies 31.7% of market share in 2022 globally. UTI is one of the most common bacterial-caused infectious illnesses in the country. A complex urinary tract infection, which is caused by anatomical or functional abnormalities in the urinary system, can afflict anyone, regardless of gender or age.
To avoid complications and achieve optimal patient outcomes, there is a growing emphasis on precise diagnosis and effective therapy of UTIs. As healthcare professionals and patients become more aware of the necessity of diagnostic testing, the demand for UTI tests is increasing.
China expenditure on urinary tract infection testing in 2022 was US$ 32.5 Million.
Several policies and programmes have been developed by the Chinese government to enhance healthcare outcomes and minimise healthcare-associated infections, including UTIs.
One key undertaking is the promotion of infection prevention knowledge and education. The goal is to raise awareness among healthcare practitioners and patients about the danger of UTIs and the need of infection prevention.
The government provides healthcare providers with training and instruction to help them improve their knowledge and skills in preventing UTIs. They also concentrate on this effort. Furthermore, encouraging the use of infection prevention measures in healthcare facilities. As a result, China is in high demand in the testing market for urinary tract infections.
In 2022, the Germany held a significant share in the European market and contributed around 23.1% value share in 2022. Germany has a well-developed healthcare system that places a high emphasis on diagnostic services and preventive treatment. The availability of improved healthcare infrastructure, such as diagnostic laboratories and clinics, helps to drive the UTI testing market forward. The rising prevalence of UTIs in the country contributes to the development of the UTI testing market.
UTIs are a widespread health problem in Germany, affecting a large number of people each year. UTIs are becoming more common due to factors such as an ageing population, lifestyle changes, and healthcare-associated illnesses. In Germany, this fuels the demand for UTI testing.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By test, urinalysis held 48.5% market share in world in 2022.
Urinalysis tests are widely used. They are a simple and non-invasive approach for healthcare experts to assess numerous different elements of human health. Urinalysis is frequently used by healthcare providers to screen for or monitor several common health disorders, such as liver disease, kidney disease, and diabetes. These tests' broad applicability are the reason for their significant market share.
The market value of laboratory test kits is representing a sizable 73.3% market share in 2022.
Most laboratories use leukocyte esterase rapid tests to replace microscopic leukocyte counts in urine. A more advanced and exact laboratory investigation of the urine validates the results of these test kits. Because of their precision, these test kits are gaining popularity and assisting in market expansion.
The Cystitis have a considerable presence in the market with market share of 58.6% in 2022. Due to the ageing population, cystitis is the most prevalent type of UTI. Cystitis is frequent in the elderly, especially when they are ill. Bladder catheters and some urinary-tract procedures may further raise the risk of cystitis.
The hospitals have a considerable presence in the urinary tract infection testing market, accounting for 41.7% value share in 2022, and exhibiting a high CAGR of 6.5% over the forecast period. The increased use of laboratory kits in hospitals for UTI detection is resulting in more potent for the UTI treatment, as well as increased patient visits in the hospitals globally each year are aiding the growth of the market.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten urinary tract infection testing. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of urinary tract infection testing. Among the well-known players in this field are:
Similarly, recent developments related to the companies active in the urinary tract infection testing market have been tracked by the team at Future Market Insights, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | US$ Million for Value, Units for Volume |
Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
Key Market Segments Covered | Test, Test Kits, Indication, End User, and Region |
Key Companies Profiled | ACON Laboratories Inc.; Cardinal Health Inc.; Danaher Corporation; SYSMEX CORPORATION; Abbott Laboratories; Bio-Rad Laboratories; Roche AG; LabCorp (Laboratory Corporation of America Holdings).; Stryker Corporation; Thermo Fisher Scientific, Inc. |
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Pricing | Available upon Request |
The overall market was valued at around US$ 563 million in 2022 end.
The adoption of urinary tract infection testing services could grow at 6% annually until 2033.
The global market value to cross US$ 1,100 million by 2033.
The United States alone had generated nearly 31.7% of the global demand in 2022.
China market accrued nearly US$ 32.5 million in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Key Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption/Usage Analysis
4.2. Key Regulations
4.3. Value Chain Analysis
4.4. PESTEL Analysis
4.5. Key Deals and Mergers
4.6. List of Service Providers, By Key Countries
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Infectious Disease Diagnostics Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Elderly Population
5.2.2. Rise in Chronic and Infectious Disease Prevalence
5.2.3. Rising Research and Development
5.2.4. Enhancing Healthcare Infrastructure
5.2.5. Government Regulations in Product Approval
5.2.6. Increasing Incidences of Catheter Associated UTI
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2017 to 2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis By Tests
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Mn) Analysis 2017 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033, By Tests
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Tests, 2017 - 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests, 2023 - 2033
9.3.1. Urinalysis
9.3.2. Urine Cultures
9.3.3. Susceptibility Testing
9.4. Market Attractiveness Analysis By Tests
10. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033, By Test Kits
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Test Kits , 2017 - 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Test Kits, 2023 - 2033
10.3.1. Home Test Kits
10.3.2. Laboratory Test Kits
10.4. Market Attractiveness Analysis By Test Kits
11. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 - 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 - 2033
11.3.1. Cystitis
11.3.2. Urethritis
11.3.3. Pyelonephritis
11.4. Market Attractiveness Analysis By Indication
12. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By End User, 2017 - 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 - 2033
12.3.1. Hospitals
12.3.2. Nephropathy Clinics
12.3.3. Diagnostic Laboratories
12.3.4. others
12.4. Market Attractiveness Analysis By End User
13. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033, By Region
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Tests
14.3.3. By Test Kits
14.3.4. By Indication
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Tests
14.4.3. By Test Kits
14.4.4. By Indication
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. USA Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast By Market Taxonomy
14.8.1.2.1. By Tests
14.8.1.2.2. By Test Kits
14.8.1.2.3. By Indication
14.8.1.2.4. By End User
14.8.2. Canada Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast By Market Taxonomy
14.8.2.2.1. By Tests
14.8.2.2.2. By Test Kits
14.8.2.2.3. By Indication
14.8.2.2.4. By End User
15. Latin America Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.1.4.1. By Country
15.3.1.4.2. By Tests
15.3.1.4.3. By Test Kits
15.3.1.4.4. By Indication
15.3.1.4.5. By End User
15.4. Market Attractiveness Analysis
15.4.1.1.1. By Country
15.4.1.1.2. By Tests
15.4.1.1.3. By Test Kits
15.4.1.1.4. By Indication
15.4.1.1.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Mexico Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast By Market Taxonomy
15.8.1.2.1. By Tests
15.8.1.2.2. By Test Kits
15.8.1.2.3. By Indication
15.8.1.2.4. By End User
15.8.2. Brazil Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast By Market Taxonomy
15.8.2.2.1. By Tests
15.8.2.2.2. By Test Kits
15.8.2.2.3. By Indication
15.8.2.2.4. By End User
15.8.3. Argentina Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast By Market Taxonomy
15.8.3.2.1. By Tests
15.8.3.2.2. By Test Kits
15.8.3.2.3. By Indication
15.8.3.2.4. By End User
16. Europe Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. UK
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Tests
16.3.3. By Test Kits
16.3.4. By Indication
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Tests
16.4.3. By Test Kits
16.4.4. By Indication
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Germany Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast By Market Taxonomy
16.8.1.2.1. By Tests
16.8.1.2.2. By Test Kits
16.8.1.2.3. By Indication
16.8.1.2.4. By End User
16.8.2. Italy Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast By Market Taxonomy
16.8.2.2.1. By Tests
16.8.2.2.2. By Test Kits
16.8.2.2.3. By Indication
16.8.2.2.4. By End User
16.8.3. France Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast By Market Taxonomy
16.8.3.2.1. By Tests
16.8.3.2.2. By Test Kits
16.8.3.2.3. By Indication
16.8.3.2.4. By End User
16.8.4. UK Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast By Market Taxonomy
16.8.4.2.1. By Tests
16.8.4.2.2. By Test Kits
16.8.4.2.3. By Indication
16.8.4.2.4. By End User
16.8.5. Spain Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast By Market Taxonomy
16.8.5.2.1. By Tests
16.8.5.2.2. By Test Kits
16.8.5.2.3. By Indication
16.8.5.2.4. By End User
16.8.6. BENELUX Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast By Market Taxonomy
16.8.6.2.1. By Tests
16.8.6.2.2. By Test Kits
16.8.6.2.3. By Indication
16.8.6.2.4. By End User
16.8.7. Russia Market Analysis
16.8.7.1. Introduction
16.8.7.2. Market Analysis and Forecast By Market Taxonomy
16.8.7.2.1. By Tests
16.8.7.2.2. By Test Kits
16.8.7.2.3. By Indication
16.8.7.2.4. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Tests
17.3.3. By Test Kits
17.3.4. By Indication
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Tests
17.4.3. By Test Kits
17.4.4. By Indication
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast By Market Taxonomy
17.8.1.2.1. By Tests
17.8.1.2.2. By Test Kits
17.8.1.2.3. By Indication
17.8.1.2.4. By End User
17.8.2. Japan Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast By Market Taxonomy
17.8.2.2.1. By Tests
17.8.2.2.2. By Test Kits
17.8.2.2.3. By Indication
17.8.2.2.4. By End User
17.8.3. South Korea Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast By Market Taxonomy
17.8.3.2.1. By Tests
17.8.3.2.2. By Test Kits
17.8.3.2.3. By Indication
17.8.3.2.4. By End User
18. South Asia Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Tests
18.3.3. By Test Kits
18.3.4. By Indication
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Tests
18.4.3. By Test Kits
18.4.4. By Indication
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. India Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast By Market Taxonomy
18.8.1.2.1. By Tests
18.8.1.2.2. By Test Kits
18.8.1.2.3. By Indication
18.8.1.2.4. By End User
18.8.2. Indonesia Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast By Market Taxonomy
18.8.2.2.1. By Tests
18.8.2.2.2. By Test Kits
18.8.2.2.3. By Indication
18.8.2.2.4. By End User
18.8.3. Malaysia Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast By Market Taxonomy
18.8.3.2.1. By Tests
18.8.3.2.2. By Test Kits
18.8.3.2.3. By Indication
18.8.3.2.4. By End User
18.8.4. Thailand Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast By Market Taxonomy
18.8.4.2.1. By Tests
18.8.4.2.2. By Test Kits
18.8.4.2.3. By Indication
18.8.4.2.4. By End User
19. Oceania Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Tests
19.3.3. By Test Kits
19.3.4. By Indication
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Tests
19.4.3. By Test Kits
19.4.4. By Indication
19.4.5. By End User
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. Australia Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast By Market Taxonomy
19.7.1.2.1. By Tests
19.7.1.2.2. By Test Kits
19.7.1.2.3. By Indication
19.7.1.2.4. By End User
19.7.2. New Zealand Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast By Market Taxonomy
19.7.2.2.1. By Tests
19.7.2.2.2. By Test Kits
19.7.2.2.3. By Indication
19.7.2.2.4. By End User
20. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis & Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. South Africa
20.3.1.4. Northern Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Tests
20.3.3. By Test Kits
20.3.4. By Indication
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Tests
20.4.3. By Test Kits
20.4.4. By Indication
20.4.5. By End User
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. GCC Countries Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast By Market Taxonomy
20.8.1.2.1. By Tests
20.8.1.2.2. By Test Kits
20.8.1.2.3. By Indication
20.8.1.2.4. By End User
20.8.2. Türkiye Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast By Market Taxonomy
20.8.2.2.1. By Tests
20.8.2.2.2. By Test Kits
20.8.2.2.3. By Indication
20.8.2.2.4. By End User
20.8.3. South Africa Market Analysis
20.8.3.1. Introduction
20.8.3.2. Market Analysis and Forecast By Market Taxonomy
20.8.3.2.1. By Tests
20.8.3.2.2. By Test Kits
20.8.3.2.3. By Indication
20.8.3.2.4. By End User
20.8.4. Northern Africa Market Analysis
20.8.4.1. Introduction
20.8.4.2. Market Analysis and Forecast By Market Taxonomy
20.8.4.2.1. By Tests
20.8.4.2.2. By Test Kits
20.8.4.2.3. By Indication
20.8.4.2.4. By End User
21. Market Structure Analysis
21.1. Market Analysis By Tier of Companies
21.2. Market Concentration
21.3. Market Share Analysis (%) of Top Players
21.4. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. ACON Laboratories Inc.
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Sales Footprint
22.3.1.4. Key Financials
22.3.1.5. SWOT Analysis
22.3.1.6. Strategic Overview
22.3.1.6.1. Marketing Strategy
22.3.1.6.2. Product Strategy
22.3.1.6.3. Channel Strategy
22.3.2. Cardinal Health Inc.
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Sales Footprint
22.3.2.4. Key Financials
22.3.2.5. SWOT Analysis
22.3.2.6. Strategic Overview
22.3.2.6.1. Marketing Strategy
22.3.2.6.2. Product Strategy
22.3.2.6.3. Channel Strategy
22.3.3. Danaher Corporation
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Sales Footprint
22.3.3.4. Key Financials
22.3.3.5. SWOT Analysis
22.3.3.6. Strategic Overview
22.3.3.6.1. Marketing Strategy
22.3.3.6.2. Product Strategy
22.3.3.6.3. Channel Strategy
22.3.4. SYSMEX CORPORATION
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Sales Footprint
22.3.4.4. Key Financials
22.3.4.5. SWOT Analysis
22.3.4.6. Strategic Overview
22.3.4.6.1. Marketing Strategy
22.3.4.6.2. Product Strategy
22.3.4.6.3. Channel Strategy
22.3.5. Abbott Laboratories
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Sales Footprint
22.3.5.4. Key Financials
22.3.5.5. SWOT Analysis
22.3.5.6. Strategic Overview
22.3.5.6.1. Marketing Strategy
22.3.5.6.2. Product Strategy
22.3.5.6.3. Channel Strategy
22.3.6. Bio-Rad Laboratories
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Sales Footprint
22.3.6.4. Key Financials
22.3.6.5. SWOT Analysis
22.3.6.6. Strategic Overview
22.3.6.6.1. Marketing Strategy
22.3.6.6.2. Product Strategy
22.3.6.6.3. Channel Strategy
22.3.7. Roche AG
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Sales Footprint
22.3.7.4. Key Financials
22.3.7.5. SWOT Analysis
22.3.7.6. Strategic Overview
22.3.7.6.1. Marketing Strategy
22.3.7.6.2. Product Strategy
22.3.7.6.3. Channel Strategy
22.3.8. LabCorp (Laboratory Corporation of America Holdings).
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Sales Footprint
22.3.8.4. Key Financials
22.3.8.5. SWOT Analysis
22.3.8.6. Strategic Overview
22.3.8.6.1. Marketing Strategy
22.3.8.6.2. Product Strategy
22.3.8.6.3. Channel Strategy
22.3.9. Stryker Corporation
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Sales Footprint
22.3.9.4. Key Financials
22.3.9.5. SWOT Analysis
22.3.9.6. Strategic Overview
22.3.9.6.1. Marketing Strategy
22.3.9.6.2. Product Strategy
22.3.9.6.3. Channel Strategy
22.3.10. Thermo Fisher Scientific, Inc.
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Sales Footprint
22.3.10.4. Key Financials
22.3.10.5. SWOT Analysis
22.3.10.6. Strategic Overview
22.3.10.6.1. Marketing Strategy
22.3.10.6.2. Product Strategy
22.3.10.6.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports